A detailed history of Citigroup Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 107,384 shares of BEAM stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,384
Previous 90,335 18.87%
Holding current value
$2.72 Million
Previous $2.12 Million 24.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$22.57 - $33.14 $384,795 - $565,003
17,049 Added 18.87%
107,384 $2.63 Million
Q2 2024

Aug 12, 2024

SELL
$21.22 - $32.66 $3.58 Million - $5.51 Million
-168,851 Reduced 65.15%
90,335 $2.12 Million
Q1 2024

May 10, 2024

BUY
$23.46 - $45.07 $1.68 Million - $3.23 Million
71,598 Added 38.17%
259,186 $8.56 Million
Q4 2023

Feb 09, 2024

SELL
$17.69 - $30.76 $177,059 - $307,876
-10,009 Reduced 5.07%
187,588 $5.11 Million
Q3 2023

Nov 09, 2023

BUY
$23.01 - $32.46 $804,038 - $1.13 Million
34,943 Added 21.48%
197,597 $4.75 Million
Q2 2023

Aug 10, 2023

SELL
$29.32 - $35.99 $1.67 Million - $2.05 Million
-56,847 Reduced 25.9%
162,654 $5.19 Million
Q1 2023

May 11, 2023

BUY
$30.15 - $48.79 $3.09 Million - $5 Million
102,451 Added 87.53%
219,501 $6.72 Million
Q4 2022

Feb 09, 2023

SELL
$36.73 - $51.6 $665,327 - $934,682
-18,114 Reduced 13.4%
117,050 $4.58 Million
Q3 2022

Nov 10, 2022

SELL
$39.79 - $70.31 $760,148 - $1.34 Million
-19,104 Reduced 12.38%
135,164 $6.44 Million
Q2 2022

Aug 10, 2022

BUY
$29.86 - $62.36 $3.09 Million - $6.46 Million
103,543 Added 204.13%
154,268 $5.97 Million
Q1 2022

May 12, 2022

SELL
$53.73 - $82.16 $1.97 Million - $3.01 Million
-36,578 Reduced 41.9%
50,725 $2.91 Million
Q4 2021

Feb 10, 2022

BUY
$68.02 - $99.06 $3.2 Million - $4.65 Million
46,989 Added 116.56%
87,303 $6.96 Million
Q3 2021

Nov 10, 2021

BUY
$84.37 - $133.6 $3.4 Million - $5.39 Million
40,314 New
40,314 $3.51 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.